Metformin use and the risk of colorectal adenoma: A systematic review and meta-analysis

Journal of Gastroenterology and Hepatology (Australia)

Volumn 32, Issue 5, 2017, Pages 957-965

  Jung, Yoon Suk ^a   Park, Chan Hyuk ^b   Eun, Chang Soo ^b   Park, Dong Il ^a   Han, Dong Soo ^b  

^a Sungkyunkwan University School of Medicine   (South Korea)

^b Hanyang University Guri Hospital   (South Korea)

Author keywords

chemoprevention; colorectal adenoma; metformin

Indexed keywords

ACETYLSALICYLIC ACID; HEMOGLOBIN A1C; INSULIN; LIPID; METFORMIN;

ARTICLE; CANCER RISK; CLINICAL EVALUATION; COCHRANE LIBRARY; COLON TUMOR; COLORECTAL ADENOMA; COLORECTAL POLYP; COLORECTAL TUMOR; DIABETES MELLITUS; DISEASE ASSOCIATION; DRUG EXPOSURE; EMBASE; HIGH RISK POPULATION; HUMAN; MEDICAL HISTORY; MEDLINE; META ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; RISK FACTOR; SYSTEMATIC REVIEW; ADENOMA; BIBLIOGRAPHIC DATABASE; COLORECTAL NEOPLASMS; COMPLICATION; DIABETIC COMPLICATION; ODDS RATIO; RISK;

ADENOMA; COLORECTAL NEOPLASMS; DATABASES, BIBLIOGRAPHIC; DIABETES COMPLICATIONS; DIABETES MELLITUS; HUMANS; METFORMIN; ODDS RATIO; RISK;

EID: 85018682980     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/jgh.13639     Document Type: Article

References (46)

1. Lin OS, Kozarek RA, Cha JM. Impact of sigmoidoscopy and colonoscopy on colorectal cancer incidence and mortality: an evidence-based review of published prospective and retrospective studies. Intest. Res. 2014; 12: 268–274.
2. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int. J. Cancer 2010; 127: 2893–2917.
3. Ng SC, Wong SH. Colorectal cancer screening in Asia. Br. Med. Bull. 2013; 105: 29–42.
4. Nathan DM, Buse JB, Davidson MB et al. Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 2009; 52: 17–30.
5. Papanas N, Maltezos E, Mikhailidis DP. Metformin: diamonds are forever. Expert Opin. Pharmacother. 2009; 10: 2395–2397.
6. Kourelis TV, Siegel RD. Metformin and cancer: new applications for an old drug. Med. Oncol. 2012; 29: 1314–1327.
7. Nangia-Makker P, Yu Y, Vasudevan A et al. Metformin: a potential therapeutic agent for recurrent colon cancer. PLoS One 2014; 9: e84369.
8. Mei ZB, Zhang ZJ, Liu CY et al. Survival benefits of metformin for colorectal cancer patients with diabetes: a systematic review and meta-analysis. PLoS One 2014; 9: e91818.
9. He XK, Su TT, Si JM, Sun LM. Metformin is associated with slightly reduced risk of colorectal cancer and moderate survival benefits in diabetes mellitus: a meta-analysis. Medicine (Baltimore) 2016; 95: e2749.
10. Nie Z, Zhu H, Gu M. Reduced colorectal cancer incidence in type 2 diabetic patients treated with metformin: a meta-analysis. Pharm. Biol. 2016; 1-7.
11. Rokkas T, Portincasa. colon neoplasia in patients with type 2 diabetes on metformin: a meta-analysis. Eur. J. Intern. Med. 2016; 33: 60–66.
12. Brenner H, Kloor M, Pox CP. Colorectal cancer. Lancet 2014; 383: 1490–1502.
13. Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur. J. Epidemiol. 2010; 25: 603–605.
14. Wells G, Shea B, O'Connell D et al. The Newcastle-Ottawa scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses, Available at: http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp. Accessed January 9, 2016.
15. Castillo JJ, Mull N, Reagan JL, Nemr S, Mitri J. Increased incidence of non-Hodgkin lymphoma, leukemia, and myeloma in patients with diabetes mellitus type 2: a meta-analysis of observational studies. Blood 2012; 119: 4845–4850.
16. Singh S, Singh PP, Singh AG, Murad MH, Sanchez W. Statins are associated with a reduced risk of hepatocellular cancer: a systematic review and meta-analysis. Gastroenterology 2013; 144: 323–332.
17. Park CH, Kim EH, Roh YH, Kim HY, Lee SK. The association between the use of proton pump inhibitors and the risk of hypomagnesemia: a systematic review and meta-analysis. PLoS One 2014; 9: e112558.
18. Higgins J, Altman DG, Sterne J. Cochrnae handbook for systematic reviews of interventions, version 5.1.0, chapter 8: assessing risk of bias in included studies, Available at: http://handbook.cochrane.org/chapter_8/8_assessing_risk_of_bias_in_included_studies.htm. Accessed January 31, 2016. 2011.
19. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin. Trials 1986; 7: 177–188.
20. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003; 327: 557–560.
21. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994; 50: 1088–1101.
22. Easterbrook PJ, Berlin JA, Gopalan R, Matthews DR. Publication bias in clinical research. Lancet 1991; 337: 867–872.
23. Duval S, Tweedie R. Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics 2000; 56: 455–463.
24. Liberati A, Altman DG, Tetzlaff J et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J. Clin. Epidemiol. 2009; 62: e1–34.
25. Chung YW, Han DS, Park KH, Eun CS, Yoo KS, Park CK. Insulin therapy and colorectal adenoma risk among patients with Type 2 diabetes mellitus: a case–control study in Korea. Dis. Colon rectum 2008; 51: 593–597.
26. Eddi R, Karki A, Shah A, DeBari VA, DePasquale JR. Association of type 2 diabetes and colon adenomas. J. Gastrointest. Cancer 2012; 43: 87–92.
27. Lee JH, Jeon SM, Hong SP, Cheon JH, Kim TI, Kim WH. Metformin use is associated with a decreased incidence of colorectal adenomas in diabetic patients with previous colorectal cancer. Dig. Liver Dis. 2012; 44: 1042–1047.
28. Wong P, Weiner MG, Hwang WT, Yang YX. Insulin therapy and colorectal adenomas in patients with diabetes mellitus. Cancer Epidemiol. Biomarkers Prev. 2012; 21: 1833–1840.
29. Kanadiya MK, Gohel TD, Sanaka MR, Thota PN, Shubrook JH Jr. Relationship between type-2 diabetes and use of metformin with risk of colorectal adenoma in an American population receiving colonoscopy. J. Diabetes Complications 2013; 27: 463–466.
30. Cho YH, Ko BM, Kim SH et al. Does metformin affect the incidence of colonic polyps and adenomas in patients with type 2 diabetes mellitus? Intest. Res. 2014; 12: 139–145.
31. Kim YH, Noh R, Cho SY et al. Inhibitory effect of metformin therapy on the incidence of colorectal advanced adenomas in patients with diabetes. Intest. Res. 2015; 13: 145–152.
32. Marks AR, Pietrofesa RA, Jensen CD, Zebrowski A, Corley DA, Doubeni CA. Metformin use and risk of colorectal adenoma after polypectomy in patients with type 2 diabetes mellitus. Cancer Epidemiol. Biomarkers Prev. 2015; 24: 1692–1698.
33. Jain D, Chhoda A, Uribe J. Effect of insulin and metformin combination treatment on colon adenoma and advanced adenoma among DM II. J. Gastrointest. Cancer 2016; 47: 404–408.
34. Higurashi T, Hosono K, Takahashi H et al. Metformin for chemoprevention of metachronous colorectal adenoma or polyps in post-polypectomy patients without diabetes: a multicentre double-blind, placebo-controlled, randomised phase 3 trial. Lancet Oncol. 2016; 17: 475–483.
35. Yu F, Guo Y, Wang H et al. Type 2 diabetes mellitus and risk of colorectal adenoma: a meta-analysis of observational studies. BMC Cancer 2016; 16: 642.
36. Singh S, Singh H, Singh PP, Murad MH, Limburg PJ. Antidiabetic medications and the risk of colorectal cancer in patients with diabetes mellitus: a systematic review and meta-analysis. Cancer Epidemiol. Biomarkers Prev. 2013; 22: 2258–2268.
37. Lin CM, Huang HL, Chu FY et al. Association between gastroenterological malignancy and diabetes mellitus and anti-diabetic therapy: a nationwide, population-based cohort study. PLoS One 2015; 10: e0125421.
38. Tsilidis KK, Capothanassi D, Allen NE et al. Metformin does not affect cancer risk: a cohort study in the U.K. Clinical Practice Research Datalink analyzed like an intention-to-treat trial. Diabetes Care 2014; 37: 2522–2532.
39. Currie CJ, Poole CD, Gale EA. The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia 2009; 52: 1766–1777.
40. Medical Advisory Secretariat. Behavioural interventions for type 2 diabetes: an evidence-based analysis. Ont. Health Technol. Assess. Ser. 2009; 9: 1–45.
41. Bajwa SJ, Sehgal V, Kalra S, Baruah MP. Management of diabetes mellitus type-2 in the geriatric population: current perspectives. J. Pharm. Bioallied. Sci. 2014; 6: 151–157.
42. Benedix F, Meyer F, Kube R, Gastinger I, Lippert H. Right- and left-sided colonic cancer – different tumour entities. Zentralbl. Chir. 2010; 135: 312–317.
43. Deming DA, Leystra AA, Farhoud M et al. mTOR inhibition elicits a dramatic response in PI3K-dependent colon cancers. PLoS One 2013; 8: e60709.
44. Lewis JD, Capra AM, Achacoso NS et al. Thiazolidinedione therapy is not associated with increased colonic neoplasia risk in patients with diabetes mellitus. Gastroenterology 2008; 135: 1914–1923.23.e1
45. Lee HS, Jeon SW. Is retroflexion helpful in detecting adenomas in the right colon?: A single center interim analysis. Intest. Res. 2015; 13: 326–331.
46. Benedix F, Kube R, Meyer F, Schmidt U, Gastinger I, Lippert H. Comparison of 17,641 patients with right- and left-sided colon cancer: differences in epidemiology, perioperative course, histology, and survival. Dis. Colon rectum 2010; 53: 57–64.